Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 442 results for cardiovascular disease

  1. MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)

    NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .

    Medtech innovation briefing
    Published
    11 October 2019

  2. Patient decision aids

    Intrabeam radiotherapy for treating early breast cancer Cardiovascular conditions (heart disease and stroke) How do I...

  3. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA814

  4. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....

    Research recommendation
    Published
    9 June 2015

  5. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

    Technology appraisal guidance
    Published
    14 December 2016
    View recommendations

    Sections for TA420

  6. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

    Clinical guideline
    Published
    28 October 2009
    View recommendations

    Sections for CG91

  7. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    data. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015

  8. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Last updated
    26 October 2018
    View recommendations

    Sections for TA221

  9. Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    4 January 2023
    View recommendations

    Sections for TA856

  10. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    adults unless contraindicated (adults over 65 or with a history of cardiovascular disease). Although evidence about dosing was very...

    Research recommendation
    Published
    10 February 2020

  11. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA561

  12. Balloon valvuloplasty for aortic valve stenosis in adults and children (HTG49)

    Evidence-based recommendations on balloon valvuloplasty for aortic valve stenosis in adults and children. This involves inflating a balloon inserted into the narrow valve to widen it so that blood can flow out more easily.

    HealthTech guidance
    Published
    28 July 2004
    View recommendations

    Sections for HTG49

  13. Radiofrequency valvotomy for pulmonary atresia (HTG57)

    Evidence-based recommendations on radiofrequency valvotomy for pulmonary atresia. This involves making a hole in the blocked valve, and inserting and inflating a small balloon to widen it.

    HealthTech guidance
    Published
    27 October 2004
    View recommendations

    Sections for HTG57

  14. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  15. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    risk. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification

    Research recommendation
    Published
    9 June 2015